Business Description
TaiGen Biopharmaceuticals Holdings Ltd
ISIN : KYG866171005
Total Employee Number:
77Description
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other. The majority of the revenue is generated from development, research and sales of new drugs.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 20.86 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | 0.64 | |||||
Interest Coverage | 41.68 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 44.37 | |||||
Beneish M-Score | -2.05 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 92.2 | |||||
3-Year Book Growth Rate | 3.7 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.76 | |||||
9-Day RSI | 49.6 | |||||
14-Day RSI | 48.85 | |||||
3-1 Month Momentum % | -17.67 | |||||
6-1 Month Momentum % | -39.59 | |||||
12-1 Month Momentum % | 6.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.48 | |||||
Quick Ratio | 12.56 | |||||
Cash Ratio | 12.35 | |||||
Days Inventory | 1069.26 | |||||
Days Sales Outstanding | 9.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | 0.7 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93 | |||||
Operating Margin % | 26.74 | |||||
Net Margin % | 17.41 | |||||
EBITDA Margin % | 29.51 | |||||
FCF Margin % | 6.33 | |||||
OCF Margin % | 8.07 | |||||
ROE % | 4.46 | |||||
ROA % | 4.02 | |||||
ROIC % | 42.92 | |||||
3-Year ROIIC % | -2006.82 | |||||
ROC (Joel Greenblatt) % | 72.33 | |||||
ROCE % | 5.64 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 147.84 | |||||
PE Ratio without NRI | 161.27 | |||||
Shiller PE Ratio | 479.9 | |||||
Price-to-Owner-Earnings | 276.67 | |||||
PS Ratio | 24.36 | |||||
PB Ratio | 5.88 | |||||
Price-to-Tangible-Book | 5.99 | |||||
Price-to-Free-Cash-Flow | 422.39 | |||||
Price-to-Operating-Cash-Flow | 316.78 | |||||
EV-to-EBIT | 90.29 | |||||
EV-to-EBITDA | 69.68 | |||||
EV-to-Revenue | 20.56 | |||||
EV-to-FCF | 336.19 | |||||
Price-to-GF-Value | 0.26 | |||||
Price-to-Projected-FCF | 6.03 | |||||
Price-to-Median-PS-Value | 0.13 | |||||
Price-to-Graham-Number | 6.57 | |||||
| Price-to-Net-Current-Asset-Value | 6.16 | |||||
| Price-to-Net-Cash | 6.77 | |||||
Earnings Yield (Greenblatt) % | 1.11 | |||||
FCF Yield % | 0.26 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TaiGen Biopharmaceuticals Holdings Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 259.474 | ||
| EPS (TTM) (NT$) | 0.06 | ||
| Beta | 0.1667 | ||
| 3-Year Sharpe Ratio | -0.69 | ||
| 3-Year Sortino Ratio | -1.04 | ||
| Volatility % | 53.11 | ||
| 14-Day RSI | 48.85 | ||
| 14-Day ATR (NT$) | 0.256369 | ||
| 20-Day SMA (NT$) | 8.777 | ||
| 12-1 Month Momentum % | 6.88 | ||
| 52-Week Range (NT$) | 7.44 - 16.4 | ||
| Shares Outstanding (Mil) | 711.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TaiGen Biopharmaceuticals Holdings Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TaiGen Biopharmaceuticals Holdings Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
TaiGen Biopharmaceuticals Holdings Ltd Frequently Asked Questions
What is TaiGen Biopharmaceuticals Holdings Ltd(ROCO:4157)'s stock price today?
The current price of ROCO:4157 is NT$8.87. The 52 week high of ROCO:4157 is NT$16.40 and 52 week low is NT$7.44.
When is next earnings date of TaiGen Biopharmaceuticals Holdings Ltd(ROCO:4157)?
The next earnings date of TaiGen Biopharmaceuticals Holdings Ltd(ROCO:4157) is .
Does TaiGen Biopharmaceuticals Holdings Ltd(ROCO:4157) pay dividends? If so, how much?
TaiGen Biopharmaceuticals Holdings Ltd(ROCO:4157) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on TaiGen Biopharmaceuticals Holdings Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers